These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31300214)

  • 21. Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review.
    Michalarea V; Fontana E; Garces AI; Williams A; Smyth EC; Picchia S; Rao S; Chau I; Cunningham D; Bali MA
    Curr Probl Cancer; 2019 Oct; 43(5):487-494. PubMed ID: 30827742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.
    Tanizaki J; Hayashi H; Kimura M; Tanaka K; Takeda M; Shimizu S; Ito A; Nakagawa K
    Lung Cancer; 2016 Dec; 102():44-48. PubMed ID: 27987588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
    Swami U; Smith M; Zhang J
    J Thorac Oncol; 2018 Sep; 13(9):e183-e184. PubMed ID: 30166022
    [No Abstract]   [Full Text] [Related]  

  • 24. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
    Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
    Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential CT Findings in Patients With Non-small-cell Lung Cancer Receiving Nivolumab.
    Johnson DY; Short RG; Patz EF
    Clin Lung Cancer; 2018 Mar; 19(2):175-180. PubMed ID: 29153896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma.
    Ikeda T; Yamaguchi H; Dotsu Y; Taniguchi H; Gyoutoku H; Senju H; Sakamoto N; Iwanaga S; Kuwatsuka Y; Fukuda M; Mukae H
    Thorac Cancer; 2018 Nov; 9(11):1522-1524. PubMed ID: 30253076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
    Krefting F; Basara N; Schütte W; Späth-Schwalbe E; Alt J; Thiel S; Kimmich M; Fischer JR; Kurz S; Griesinger F; Christoph DC
    Oncol Res Treat; 2019; 42(5):243-255. PubMed ID: 30995666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
    Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab.
    Agulló-Ortuño MT; Gómez-Martín Ó; Ponce S; Iglesias L; Ojeda L; Ferrer I; García-Ruiz I; Paz-Ares L; Pardo-Marqués V
    Clin Lung Cancer; 2020 Jan; 21(1):75-85. PubMed ID: 31562055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nivolumab improves survival for patients with advanced lung cancer.
    Printz C
    Cancer; 2017 Sep; 123(17):3211. PubMed ID: 28833027
    [No Abstract]   [Full Text] [Related]  

  • 31. Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer.
    Miyamoto S; Nomura R; Sato K; Awano N; Kuse N; Inomata M; Izumo T; Terada Y; Furuhata Y; Bae Y; Kunitoh H
    Jpn J Clin Oncol; 2019 Feb; 49(2):160-164. PubMed ID: 30452687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of gastric cancer with delayed onset of tumor reduction effect by nivolumab therapy.
    Satoyoshi R; Muto O; Masuda A; Kotanagi K; Kichiraku T; Kudoh K; Sawada T; Miyazawa H; Kotanagi H
    Clin J Gastroenterol; 2019 Feb; 12(1):15-19. PubMed ID: 30206777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
    Takeda T; Takeuchi M; Saitoh M; Takeda S
    Thorac Cancer; 2018 Oct; 9(10):1291-1299. PubMed ID: 30126063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
    de Jong C; Peters BJM; Schramel FMNH
    Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report.
    Asai M; Kato Y; Kawai S; Watanabe K; Yomota M; Okuma Y; Hosomi Y; Hishima T; Okamura T
    Immunotherapy; 2019 Apr; 11(6):467-472. PubMed ID: 30727791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.
    Alessandrino F; Sahu S; Nishino M; Adeni AE; Tirumani SH; Shinagare AB; Awad MM
    Abdom Radiol (NY); 2019 May; 44(5):1917-1927. PubMed ID: 30790009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
    Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
    Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
    Basak EA; Koolen SLW; Hurkmans DP; Schreurs MWJ; Bins S; Oomen-de Hoop E; Wijkhuijs AJM; Besten ID; Sleijfer S; Debets R; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ
    Eur J Cancer; 2019 Mar; 109():12-20. PubMed ID: 30654225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma.
    Naito T; Udagawa H; Sato J; Horinouchi H; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Ohe Y; Ishii G; Goto K
    J Thorac Oncol; 2019 Oct; 14(10):1818-1827. PubMed ID: 31260834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison Between
    Rossi G; Bauckneht M; Genova C; Rijavec E; Biello F; Mennella S; Dal Bello MG; Cittadini G; Bruzzi P; Piva R; Ceriani V; Sambuceti G; Lopci E; Morbelli S; Grossi F
    J Nucl Med; 2020 Jul; 61(7):990-998. PubMed ID: 31806768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.